Medicaid does cover drug and alcohol rehab, and for millions of low-income Americans it is the primary way addiction treatment gets paid for at all. But Medicaid coverage runs into a federal rule that most people have never heard of until they hit it directly, and understanding that rule explains almost every confusing "yes, but" you will encounter when trying to use Medicaid for residential treatment.
Medicaid is jointly funded by the federal government and individual states, and federal law has long prohibited the use of federal Medicaid dollars to pay for care provided to adults ages 21 to 64 in an "Institution for Mental Diseases," or IMD, defined as any facility with more than 16 beds that primarily provides treatment for mental health or substance use conditions. In plain terms, this means many larger residential addiction treatment centers cannot be paid through federal Medicaid funds at all, regardless of how appropriate the clinical care is.
This rule dates back decades and was originally intended to prevent states from shifting the cost of long-term institutional psychiatric care onto the federal government. But because most residential addiction treatment facilities are classified under the same regulatory umbrella as psychiatric facilities, the exclusion has ended up limiting access to residential substance use care for exactly the population Medicaid is meant to serve.
States have three main tools available to get around the IMD exclusion, and as of April 2026, 38 states plus Washington D.C. had used at least one of them, according to KFF's tracking of Medicaid IMD waivers.
| Workaround | How It Works |
|---|
| Section 1115 demonstration waivers | States apply for federal permission to cover SUD treatment in IMDs, in exchange for demonstrating a broader continuum of care and cost-neutrality to the federal government |
| SUPPORT Act state plan option | A 1915(l) option, made permanent by the 2024 Consolidated Appropriations Act, that lets states claim federal matching funds for up to 30 days per year of SUD treatment in an IMD without a full 1115 waiver |
| Managed care "in lieu of" authority | Medicaid managed care plans can cover IMD stays as a substitute for another covered service, but federal matching is capped at 15 days per enrollee per month |
Because these pathways are state-specific and each comes with its own administrative limits, whether Medicaid will pay for a residential stay at a specific facility depends heavily on which state you live in and which authority that state has adopted, not on Medicaid as a single national program.
Outside of the IMD-affected residential category, Medicaid coverage for addiction treatment is generally broader and more consistent, including:
- Outpatient counseling, individual and group
- Intensive outpatient programs (IOP)
- Partial hospitalization programs (PHP), which typically operate at facilities under 16 beds or are hospital-based
- Medication-assisted treatment, including methadone, buprenorphine, and naltrexone
- Withdrawal management and detox services, particularly in hospital-based settings
- Case management and peer recovery support services in many states
Under the Mental Health Parity and Addiction Equity Act, Medicaid managed care organizations are also required to apply the same parity protections that commercial insurers must follow, meaning treatment limits on SUD benefits cannot be more restrictive than comparable medical benefits within that plan.
Advocacy groups, including the National Alliance on Mental Illness, have pushed for years to have the IMD exclusion repealed outright, arguing that it forces a two-tiered system where Medicaid recipients face structural barriers to residential care that commercially insured patients generally do not encounter. Proponents of keeping some version of the rule in place point to its original purpose, preventing states from shifting the cost of long-term institutional psychiatric care onto the federal government and discouraging over-institutionalization of people with behavioral health conditions. That tension between expanding access and guarding against the return of large-scale, long-term institutional care is why the rule has been chipped away at through waivers and exceptions rather than repealed entirely, and why full repeal remains a live but unresolved policy debate rather than settled law.
If a residential treatment center you are considering has more than 16 beds and your state has not adopted an IMD waiver, a state plan option, or in-lieu-of authority covering that facility type, Medicaid may not pay for the stay even though it would cover an identical level of clinical care at a smaller facility. This is one of the least intuitive parts of navigating Medicaid coverage, and it is rarely explained clearly by facilities themselves, since admissions staff are focused on getting a client admitted, not walking through federal Medicaid financing structure.
Practically, this means the smartest first question to ask a facility is not "do you take Medicaid," but "does your state's Medicaid program have an IMD waiver or SUPPORT Act state plan option that covers residential treatment at a facility your size." A facility experienced with Medicaid billing should be able to answer this immediately; if they cannot, that is itself useful information.
Medicaid eligibility is based primarily on income, and thresholds vary by state, particularly in the roughly 40 states plus D.C. that have adopted Medicaid expansion under the Affordable Care Act versus the smaller number that have not. Eligibility can also depend on other factors such as pregnancy, disability status, or age. Because eligibility, covered benefits, and IMD workarounds are all determined at the state level, two people with Medicaid coverage in different states can have meaningfully different access to residential addiction treatment even with an identical diagnosis.
Consider a Medicaid recipient in a state that adopted a Section 1115 IMD waiver, seeking residential treatment at a 40-bed facility. Because the state's waiver specifically authorizes federal matching for SUD residential stays in IMDs, Medicaid can pay for that admission, provided the facility meets the state's documentation requirements around demonstrating a broader continuum of care. Now consider a Medicaid recipient in a state that has not adopted any of the three IMD workarounds, seeking care at the same size facility. Medicaid may only be able to cover the first 15 days of that stay per month through managed care in-lieu-of authority, if the plan uses that option at all, leaving a meaningful gap for anyone whose clinical needs require a longer residential stay. This is precisely why Medicaid coverage for addiction treatment cannot be evaluated as one uniform national policy. It is genuinely dependent on which of roughly 38 approved states, plus D.C., a person happens to live in, and which specific workaround that state chose to adopt.
This is not just a financing technicality. Research published on the impact of Medicaid IMD waivers found that Medicaid acceptance at residential SUD treatment facilities increased by roughly a third in states that adopted a waiver, compared to before adoption, with a smaller but still meaningful increase at intensive outpatient facilities. That data point underscores how directly this obscure federal rule shapes real-world access to residential care for Medicaid-covered patients, independent of clinical need or facility quality.
Beyond the IMD exclusion, whether someone qualifies for Medicaid at all depends on their state's approach to the Affordable Care Act's Medicaid expansion. States that adopted expansion generally extend Medicaid eligibility to adults earning up to 138 percent of the federal poverty level, which has meaningfully increased access to addiction treatment for low-income adults without children who previously had no realistic path to Medicaid coverage in many states. In the smaller number of non-expansion states, eligibility criteria tend to be narrower and often require meeting additional categories, such as disability or pregnancy, in addition to a low income. This means a person's ability to get Medicaid coverage for addiction treatment in the first place, before the IMD exclusion even becomes relevant, already varies significantly depending on where they live.
- Has my state adopted a Section 1115 SUD IMD waiver, a SUPPORT Act state plan option, or in-lieu-of managed care authority, and does the facility I am considering qualify under it?
- How many beds does this facility have, and does that put it above or below the 16-bed IMD threshold?
- If I am enrolled in Medicaid managed care, does my specific plan use in-lieu-of authority for residential SUD treatment, and what is the monthly day limit?
- Is the level of care I actually need available at a smaller facility or hospital-based unit that would not trigger the IMD exclusion at all?
- What outpatient step-down options are available once any Medicaid-covered residential days are exhausted?
If you are exploring Medicaid coverage, our broader guide to how insurance covers rehab is a useful starting point for understanding coverage concepts that apply across payer types, and if Medicaid coverage falls short for the specific level of care you need, our guide to paying for rehab without insurance outlines sliding-scale and state-funded alternatives. You can also compare inpatient versus outpatient options to see which level of care might be easier to access given your state's specific Medicaid rules.
Frequently asked questions
It is a federal rule that bars Medicaid from using federal funds to pay for care given to adults ages 21 to 64 in a facility with more than 16 beds that primarily treats mental health or substance use conditions, which affects many residential addiction treatment centers.
Not automatically. Coverage for residential treatment at larger facilities depends on whether your state has adopted a Section 1115 IMD waiver, the SUPPORT Act state plan option, or in-lieu-of managed care authority. As of April 2026, 38 states and D.C. had approved SUD IMD waivers.
Yes, outpatient counseling, intensive outpatient programs, and medication-assisted treatment are generally covered by Medicaid nationwide, since the IMD exclusion applies specifically to larger residential and inpatient facilities, not outpatient care.
Yes. Medicaid programs across all states cover MAT medications such as methadone, buprenorphine, and naltrexone for opioid and alcohol use disorder, though specific prior authorization rules can vary by state.
You can ask your state Medicaid agency directly, or ask a treatment facility's admissions or billing team whether they are able to bill Medicaid for residential stays given your state's specific waiver or state plan option status.
Yes. Medicaid managed care organizations are subject to the Mental Health Parity and Addiction Equity Act, meaning they cannot impose stricter treatment limits on substance use disorder benefits than they apply to comparable medical or surgical benefits.
This article was reviewed by the RehabsNearMe Editorial Team for accuracy, clarity, and relevance. Information may be sourced from publicly available treatment resources, government agencies, and healthcare references where applicable.
Last reviewed: September 2026
Related articles
Resources
